Additional file 3 of Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

Additional file 3: Table S3. Anti-tumor activity of sorafenib, regorafenib and DBPR114 in sorafenib-refractory HA22T/VGH xenograft tumors on day 40. HA22T/VGH tumor-bearing mice were treated with 40 mg/kg DBPR114 once a week intravenously for 6 weeks or sorafenib and regorafenib at 30 mg/kg once a day, 5 days per week orally for 40 days. Mean ± SEM, n = 8 mice per group. *p < 0.05 vs. vehicle control, **p < 0.05 vs. regorafenib, measured using  one-way ANOVA and Bonferroni posttest comparison. Table S4. Anti-tumor activity of sorafenib, regorafenib and DBPR114 in sorafenib-acquired resistant Huh7 xenograft tumors on day 25. Sorafenib-acquired resistant Huh7 tumor-bearing mice were treated with 40 mg/kg DBPR114 once a week intravenously for 3 weeks or sorafenib and regorafenib at 30 mg/kg once a day, 5 days per week orally for 25 days. Mean ± SEM, n = 8 mice per group. *p < 0.05 vs. vehicle control measured using one-way ANOVA and Bonferroni posttest comparison.